Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Kenjiro NamikawaTakamichi ItoShusuke YoshikawaKoji YoshinoYukiko KiniwaShuichi OheTaiki IseiTatsuya TakenouchiHiroshi KatoSatoru MizuhashiSatoshi FukushimaYosuke YamamotoTakashi InozumeYasuhiro FujisawaOsamu YamasakiYasuhiro NakamuraJun AsaiTakeo MaekawaTakeru FunakoshiShigeto MatsushitaEiji NakanoKohei OashiJunji KatoHisashi UharaTakuya MiyagawaHiroshi UchiNaohito HattaKeita TsutsuiTaku MaedaTaisuke MatsuyaHiroto YanagisawaIkko MutoMao OkumuraDai OgataNaoya YamazakiPublished in: Cancer medicine (2023)
The superiority of PD-1/CTLA-4 over BRAF/MEKi appears modest in Asian patients. First-line BRAF/MEKi remains feasible, but it is difficult to salvage at progression. Ethnicity should be considered when selecting systemic therapies until personalized biomarkers are available in daily practice. Further studies are needed to establish the optimal treatment sequence for Asian patients.